首页> 美国卫生研究院文献>World Journal of Gastroenterology >Therapeutic effect of DA-9601 on chronic reflux gastritis induced by sodium taurocholate in rats
【2h】

Therapeutic effect of DA-9601 on chronic reflux gastritis induced by sodium taurocholate in rats

机译:DA-9601对牛磺胆酸钠引起的慢性反流性胃炎的治疗作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the therapeutic effects of DA-9601 on sodium taurocholate (TCA)-induced chronic reflux gastritis in SD rats.METHODS: In this study, we have investigated the therapeutic effects of DA-9601 on chronic erosive and atrophic gastritis induced by 6 mo of TCA administration (5 mmol/L in drinking water) in SD rats.RESULTS: Four weeks of DA-9601 administration (0.065%, 0.216% in rat chow), following the withdrawal of TCA treatment, resulted in a significant decrease in total length of erosions in rats in a dose-dependent manner. Furthermore, the indicators of atrophic gastritis, such as reduced mucosal thickness and reduction in the number of parietal cells, were improved by the administration of DA-9601 in a dose-related manner. DA-9601 also attenuated inflammatory cell infiltration and the proliferation of collagenous fiber in the gastric mucosa. The improvement in the reduction of the gastric mucus was observed in the rats receiving a high dose of DA-9601 (0.216%). The therapeutic effect of DA-9601 on experimental chronic erosive gastritis was superior to that of rebamipide (1.08% in rat chow). Biochemical analyses showed increased mucosal prostaglandin E2 and reduced glutathione levels by DA-9601 treatment.CONCLUSION: We suggest that DA-9601 is a promising agent for the treatment of chronic erosive and atrophic gastritis with an etiological factor of bile reflux. Increased mucosal prostaglandin E2 and reduced glutathione by DA-9601 treatment may be therapeutic mechanisms for chronic erosive and atrophic gastritis.
机译:目的:探讨DA-9601对牛磺胆酸钠(TCA)诱导的SD大鼠慢性反流性胃炎的治疗作用。方法:本研究旨在探讨DA-9601对磺胺引起的慢性糜烂和萎缩性胃炎的治疗作用。结果:SD大鼠停止服用TCA 6个月(饮用水中为5 mmol / L)。结果:停药三周后,DA-9601服用了4周(0.065%,鼠为0.216%),导致显着降低在大鼠的总侵蚀中呈剂量依赖性。此外,通过以剂量相关的方式施用DA-9601,可以改善萎缩性胃炎的指标,例如减少的粘膜厚度和减少的壁细胞数量。 DA-9601还减弱了胃粘膜中的炎性细胞浸润和胶原纤维的增殖。在接受高剂量DA-9601(0.216%)的大鼠中观察到胃粘液减少的改善。 DA-9601对实验性慢性糜烂性胃炎的治疗效果优于瑞巴派特(大鼠食物的1.08%)。生化分析表明,DA-9601治疗可增加粘膜前列腺素E2含量,降低谷胱甘肽水平。结论:我们认为DA-9601是治疗慢性糜烂性萎缩性胃炎的一种有希望的药物,其病因是胆汁反流。通过DA-9601治疗,粘膜前列腺素E2升高和谷胱甘肽降低可能是慢性糜烂和萎缩性胃炎的治疗机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号